NBTGR
(Synonyms: 6-(4-硝基苄硫醇)鸟苷) 目录号 : GC32500
NBTGR(p-Nitrobenzylthioguanosine)是核苷转运(nucleosidetransport)的有效抑制剂;抑制腺苷摄取的Ki值为70nM。
Cas No.:13153-27-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
NBTGR (p-Nitrobenzylthioguanosine) is a potent inhibitor of nucleoside transport; inhibits adenosine uptake with a Ki of 70 nM.
A group of purine ribonucleosides with alkarylmercapto substituents at the purine 6-position are potent inhibitors of several aspects of nucleoside metabolism that involved the transfer of ribosyl groups. NBTGR is one of the compounds that inhibits nucleoside transport by human erythrocytes; initial rates of uridine uptake are reduced to zero upon exposure of cells to 1 μM NBTGR. The inhibitor is firmly bound because repeated washing cannot restore uridine transport capability to NBTGR-treated cells. NBTGR inhibits the influx of uridine, inosine, and cytidine, without inhibiting the uptake of the corresponding bases, or that of D-glucose or L-leucine. Uridine antagonizes the NBTGR inhibition of uidine transport in a concentration-dependent manner. NBTGR and related compounds appear to interact with the mechanism for the facilitated transport of nucleosides[2].
[1]. Turnheim K, et al. Inhibition of adenosine uptake in human erythrocytes by adenosine-5'-carboxamides, xylosyladenine, dipyridamole, hexobendine, and p-nitrobenzylthioguanosine. Biochem Pharmacol. 1978;27(18):2191-7. [2]. Parterson A, et al. Nucleoside Transport II Inhibition by p-Nitrobeazylthiogoanosine and Related Compounds. Can. J. Biochem. 49,271-274 (1971)
| Cas No. | 13153-27-0 | SDF | |
| 别名 | 6-(4-硝基苄硫醇)鸟苷 | ||
| Canonical SMILES | OC[C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C2N=C(N)N=C3SCC4=CC=C([N+]([O-])=O)C=C4)O1)O)O | ||
| 分子式 | C17H18N6O6S | 分子量 | 434.43 |
| 溶解度 | DMSO : 100 mg/mL (230.19 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3019 mL | 11.5093 mL | 23.0187 mL |
| 5 mM | 0.4604 mL | 2.3019 mL | 4.6037 mL |
| 10 mM | 0.2302 mL | 1.1509 mL | 2.3019 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet